Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 3

Sponsor Class

OTHER 20INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 5Other hematologic neoplasm 3Myeloid 2Sarcoma 1

Conditions

Thrombocytopenia 3Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Purpura, Thrombocytopenic, Idiopathic 1Myeloproliferative Disorders 1Leukemia 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × eltrombopag × Other hematologic neoplasm × Clear all
NCT01957176 2022-12-30

A Rollover Study to Provide Continued Treatment With Eltrombopag

Novartis

Phase 4 Completed
22 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myeloid, Acute, Purpura, Thrombocytopenic, Idiopathic

NCT01890746 2019-09-11

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Novartis

Phase 2 Completed
148 enrolled 42 charts
Classical hematologyOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT01440374 2017-06-05

ASPIRE

Novartis

Phase 2 Completed
162 enrolled 24 charts
Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡